The Patent Finder

Terms ending in 2039

Celgene Corporation

Every in-force patent on Celgene Corporation's record whose computed term ends in 2039, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleHolderStatusExpiresConfidence
US 11,626,210Digital Health Prognostic Analyzer for Multiple Myeloma Mortality Predictions
In force
 · High confidence
Celgene CorporationIn forceHigh confidence
US 12,474,342Methods for Treating Cancer and the Use of Biomarkers as a Predictor of Clinical Sensitivity to Therapies
In force
 · High confidence
Celgene CorporationIn forceHigh confidence
US 11,401,336Bcma-Binding Antibodies and Uses Thereof
In force
 · High confidence
Celgene CorporationIn forceHigh confidence
US 11,505,522Processes for the Preparation of (S)-TERT-BUTYL 4,5-Diamino-5-Oxopentanoate
In force
 · High confidence
Celgene CorporationIn forceHigh confidence
US 11,644,461Methods for Measuring Small Molecule Affinity to Cereblon
In force
 · High confidence
Celgene CorporationIn forceHigh confidence
US 11,358,952Substituted 4-Aminoisoindoline-1,3-Dione Compounds, Compositions Thereof, and Methods of Treatment Therewith
In force
 · High confidence
Celgene CorporationIn forceHigh confidence
US 11,357,775Combination Therapies Comprising Apremilast and TYK2 Inhibitors
In force
 · High confidence
Celgene CorporationIn forceHigh confidence
US 10,969,381Methods for Treating Multiple Myeloma and the Use of Companion Biomarkers for 4-(4-(4-(((2-(2,6-Dioxopiperidin-3-YL)-1-Oxoisoindolin-4-YL)OXY)METHYL)BENZYL)PIPERAZIN-1-YL)-3-Fluorobenzonitrile
In force
 · High confidence
Celgene CorporationIn forceHigh confidence
US 11,726,080Methods for Treating Multiple Myeloma and the Use of Companion Biomarkers for 4-(4-(4-(((2-(2,6-Dioxopiperidin-3-YL)-1-Oxoisoindolin-4-YL)OXY)METHYL)BENZYL)PIPERAZIN-1-YL)-3-Fluorobenzonitrile
In force
 · High confidence
Celgene CorporationIn forceHigh confidence
US 12,510,533Methods for Treating Multiple Myeloma and the Use of Companion Biomarkers for 4-(4-(4-(((2-(2,6-Dioxopiperidin-3-YL)-1-Oxoisoindolin-4-YL)OXY)METHYL)BENZYL)PIPERAZIN-1-YL)-3-Fluorobenzonitrile
In force
 · High confidence
Celgene CorporationIn forceHigh confidence
18 more term ends in 2039 · Pro
10 of 28 patents shown. Soonest term end first, then patent number.
Pro members see all 28.
Upgrade to Pro
26 of these are in force and held by Celgene Corporation.
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited